jRCT1061210010进行中（未招募）不适用
Efficacy and safety of zoledronic acid for postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor. (SBP-15)
未提供0 个研究点目标入组 200 人开始时间: 2021年7月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- All
入选标准
- •ER positive postmenopausal breast cancer patients
- •Patients recieving AI (<2 yerars)
- •Patients diagnosed osteoporosis
- •Patients without treatment of osteoporosis
- •CCr>35mL/min
- •Serum Ca>8.0 mg/dL
- •Without dental treatment
- •With informed consent
排除标准
- •Metastatic breast cancer patients
- •Allargy with bisphosphonate
- •Renal disfunction
- •Active other cancers
- •Treated with bisphosphonate
- •The medical doctor judged ineligible
结局指标
主要结局
-
3 years rate of bone density change
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaRelapsed or Refractory B-Cell Non-Hodgkin LymphomaMedDRA version: 25.0Level: LLTClassification code: 10086816Term: B-cell non-Hodgkin´s lymphoma refractory Class: 100000004848CTIS2023-507728-22-00F. Hoffmann-La Roche AG60
进行中（未招募）
1 期
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapyMetastatic pancreatic ductal adenocarcinoma (mPDAC)MedDRA version: 21.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104CTIS2023-508998-85-00Boehringer Ingelheim International GmbH68
进行中（未招募）
1 期
Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignanciesCTIS2023-505204-34-00Schrodinger Inc.47
招募中
1 期
A study to test different doses of BI 1831169 alone and in combination with ezabenlimab in people with different types of advanced cancer (solid tumors).solid tumorsCTIS2024-512504-19-00Boehringer Ingelheim International GmbH95
招募中
1 期
Dose escalation trial of BNT152+153 in patients with cancerVarious solid tumors that are metastatic or unresectableMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-509508-13-00BioNTech SE4